Sporadic NF2 mutations have been implicated in several cancers, including sporadic meningioma, ependymoma, and schwannoma, mesothelioma, breast cancer, hepatocellular carcinoma, prostate cancer, glioblastoma, thyroid cancer, melanoma, and renal cell carcinoma. This evidence concerns the gene NF2 and thyroid gland carcinoma.